Deals & Corporate Governance

  • June 26, 2025

    Judge Tosses Biogen MS Drug Antitrust Suit, For Now

    An Illinois federal court tossed a proposed class action accusing Biogen of reducing competition for its multiple sclerosis drug Tecfidera through payments to pharmacy benefit managers, after finding that only some drug pricing lists would have been affected.

  • June 24, 2025

    Healthcare Deals This Week: Sanofi, Abridge, Royalty Pharma

    The past week marked a busy period for dealmaking in the healthcare industry, with major partnerships and M&A announcements from companies like Royalty Pharma, Sanofi and Otsuka.

  • June 24, 2025

    AI Healthcare Startup Abridge Raises $300M Series E

    Generative artificial intelligence company Abridge has raised $300 million in a fresh round of capital, the company announced Tuesday.

  • June 24, 2025

    Cataract Surgery Tech Co. Secures $125M Series B Funding

    Ophthalmic robotic surgery company ForSight Robotics on Tuesday revealed that it completed fundraising for its Series B financing round after securing $125 million from investors.

  • June 24, 2025

    A Midyear Review: Healthcare Dealmaking Trends Of 2025

    Law360 Healthcare Authority reviews key trends that helped shape dealmaking activity in the healthcare industry so far this year.

  • June 24, 2025

    Goodwin Procter Adds PE Firm General Counsel In NY

    Goodwin Procter LLP has added the former general counsel of private equity firm Gurnet Point Capital to bolster its life sciences and healthcare practice groups.

  • June 23, 2025

    Teladoc Says Investor Suit Over User Losses Is 'Illogical'

    Telemedicine giant Teladoc Health Inc. and two of its executives seek to shed a proposed investor class action, telling a New York federal judge the shareholder suit makes "illogical" claims that they lied about post-pandemic increases in customer acquisition costs for the company's flagship mental health counseling platform.

  • June 20, 2025

    Ga. Panel Says Suit To Collect $12.1M Judgment Too Late

    The Georgia Court of Appeals on Friday said a trial court rightly found Mariner Healthcare Management Co.'s lawsuit against Sovereign Healthcare LLC over the recovery of a $12.1 million judgment was barred by the state's four-year statute of limitations for fraud.

  • June 20, 2025

    Taxation With Representation: Latham, Paul Weiss, Covington

    In this week's Taxation With Representation, Nippon Steel closes its purchase of U.S. Steel, Hunter Point Capital buys a minority stake in Equitix, Eaton acquires Ultra PCS Ltd. from the Cobham Ultra Group, and Eli Lilly and Co. acquires Verve Therapeutics.

  • June 18, 2025

    Ga. Panel Affirms Emory's Early Win In Neonatal Care Suit

    The Georgia Court of Appeals said a trial court rightly freed Emory Healthcare from a suit alleging that a nurse in the neonatal intensive care unit failed to spot an intravenous line infiltration that left a newborn with skin and tissue deformities.

  • June 18, 2025

    Spectrum Pharma Investors Get First OK For $16M Deal

    A Nevada federal judge has given the first green light to a nearly $16 million settlement between a pharmaceutical company and a class of investors who claimed the company and its executives overstated the status of two of its developed drugs and withheld negative data and trial results, leading to a stock drop when the truth was revealed.

  • June 18, 2025

    Attorneys Say Look Before Leaping Back Into Senior Housing

    Attorneys advising on senior housing deals are seeing more interest from investors and developers, due to demographic trends and the post-pandemic recovery, but emphasize the unique legal considerations of a sector that straddles healthcare and real estate.

  • June 18, 2025

    FDA Dodges Suit Over Ozempic, Wegovy Listing

    The U.S. Food and Drug Administration was able to escape allegations that it catered to Big Pharma by nixing cheaper versions of the miracle weight loss drug Ozempic, after a Texas federal judge tossed a lawsuit from two compounding pharmacies.

  • June 18, 2025

    InnovAge IPO Investors Get Initial OK Of $27M Settlement

    A Colorado federal judge has preliminarily approved a $27 million settlement between InnovAge Holding Corp., its underwriters and a class of stockholders accusing the senior-health care company of making misleading statements in an initial public offering that later caused stock prices to tank after a government audit exposed the falsehoods.

  • June 17, 2025

    Cancer Diagnostics Firm, Insurer Price 2 IPOs Totaling $902M

    Cancer-diagnostics test provider Caris Life Sciences Inc. and coastal-focused residential insurer Slide Insurance Holdings Inc. will begin trading Wednesday after pricing two initial public offerings that raised a combined $902 million, guided by five law firms.

  • June 17, 2025

    Oregon's Corporate Ownership Law Puts PE At Crossroads

    A new law in Oregon is leaving private equity firms and other organizations at a crossroads as they try to figure out how to navigate stricter rules focused on corporate ownership of healthcare practices.

  • June 17, 2025

    Surgery Partners Rejects $3.3B Bain Offer, Eyes Public Growth

    Surgery Partners, a short-stay surgical facility owner, said on Tuesday it has ended talks with Bain Capital regarding a nearly $3.3 billion take-private proposal, saying it sees a stronger future as a public company.

  • June 17, 2025

    Kirkland-Led Lilly Inks $1.3B Deal For Cardio Drug Co. Verve

    Kirkland-advised Eli Lilly and Co. said Tuesday it will acquire Paul Weiss-advised Verve Therapeutics in a deal worth up to $1.3 billion, continuing its push into next-generation genetic medicines for heart disease.

  • June 13, 2025

    AbbVie Sues Colo. Over State Discount Drug Law

    AbbVie Inc. on Thursday filed suit in Colorado federal court seeking to block an incoming state law it alleges conflicts with the federal 340B drug discount program by forcing pharmaceutical manufacturers to sell drugs at steep discounts to commercial pharmacy chains like Walgreens and CVS.

  • June 13, 2025

    Health Tech Co. Overstated AI Capabilities, Investor Suit Says

    Health technology company Tempus AI Inc. and two of its executives face a shareholder class action over claims the company misrepresented its artificial intelligence capabilities, the value of its contracts and the credibility of certain joint ventures, among other things. 

  • June 13, 2025

    Ga. Medical Co. Accused Of Infringing Swedish Co.'s Patents

    A Swedish medical device company has sued Georgia-based MedWay Group Inc. in federal court for allegedly infringing its patents for foam dressings used in wound care and management.

  • June 12, 2025

    5 Firms Guide $1.25B BioNTech, CureVac Oncology Deal

    German biotech firm BioNTech SE said Thursday that it will acquire CureVac NV, a clinical-stage mRNA specialist, in an all-stock oncology-focused deal valuing it at about $1.25 billion and involving five legal advisers. 

  • June 11, 2025

    PepGen Faces Investor Suit Over Muscular Dystrophy Drug

    Clinical-stage biotech company PepGen Inc. has been hit with a proposed shareholder class action alleging it misled investors about the efficacy and commercial prospects of its muscular dystrophy drug, causing share price declines as investors learned of the drug's clinical trials' shortcomings.

  • June 10, 2025

    Healthcare Deals This Week: Omada, Antares, Amplify

    The healthcare industry saw a few notable deals this past week, including a much-anticipated IPO from digital health company Omada and a handful of private fundraises among startups.

  • June 10, 2025

    Ill. Judge Questions Standing In Biogen Antitrust Suit

    An Illinois federal judge seemed skeptical Tuesday that health benefit plans accusing Biogen of impairing competition for its multiple sclerosis drug, Tecfidera, have standing to bring their lawsuit under decades-old precedent allowing only direct purchasers to recoup damages.

Expert Analysis

  • Legal Profession Must Do More For Lawyers With Disabilities

    Author Photo

    At the start of Disability Pride month, Rosalyn Richter at Arnold & Porter looks at why lawyers with disabilities are significantly underrepresented in private practice, asserting that law firms and other employers must do more to conquer the implicit bias that deters attorneys from seeking accommodations.

  • Scope Of FTC's Health Info Enforcement May Expand

    Author Photo

    The Federal Trade Commission's proposed amendments to the Health Breach Notification Rule signal the agency's mounting efforts to regulate consumer health information beyond the reaches of the Health Information Portability and Accountability Act, which does not cover many recent health apps and technologies, say Jodi Daniel and Brandon Ge at Crowell & Moring.

  • Appellate Funding Disclosure: No Mandate Is Right Choice

    Author Photo

    The Advisory Committee on Appellate Rules' recent decision, forgoing a mandatory disclosure rule for litigation funding in federal appeals, is prudent, as third-party funding is only involved in a minuscule number of federal cases, and courts have ample authority to obtain funding information if necessary, says Stewart Ackerly at Statera Capital.

  • How NY Law Affects Scrutiny Of Health Care PE Transactions

    Author Photo

    A recently passed New York law will strengthen pretransanction notification requirements for health care entities — particularly those backed by private equity — but contains several ambiguities that will hopefully be clarified before the law takes effect in August, say attorneys at Norton Rose.

  • How Attys Can Avoid Exposing Their Firms To Cyberattacks

    Author Photo

    Attorneys are the weakest link in their firms' cyberdefenses because hackers often exploit the gap between individuals’ work and personal cybersecurity habits, but there are some steps lawyers can take to reduce the risks they create for their employers, say Mark Hurley and Carmine Cicalese at Digital Privacy & Protection.

  • Virginia 'Rocket Docket' Slowdown Is Likely A Blip

    Author Photo

    After being the fastest or second-fastest federal civil trial court for 14 straight years, the Eastern District of Virginia has slid to 18th place, but the rocket docket’s statistical tumble doesn't mean the district no longer maintains a speedy civil docket, says Robert Tata at Hunton.

  • A Look At 2023's Major NLRB Developments Thus Far

    Author Photo

    Over the last six months, the National Labor Relations Board has broadened its interpretation and enforcement of the National Labor Relations Act, including increasing penalties and efforts to prohibit restrictive covenants and confidentiality agreements, say Eve Klein and Elizabeth Mincer at Duane Morris.

  • Preparing For Md. Adult-Use Cannabis: Licensing Provisions

    Author Photo

    As the launch of Maryland’s adult-use cannabis market quickly approaches, current and prospective businesses will need to understand key provisions and limitations related to license conversion, qualifying partnerships, social equity applications and microlicenses, say Seth Gitner and Jonathan Havens at Saul Ewing.

  • FTC's Amgen-Horizon Protest Raises Conglomerate Concerns

    Author Photo

    The Federal Trade Commission's challenge to Amgen Inc.'s proposed $28 billion acquisition of Horizon Therapeutics is the agency's first move in four decades based on a conglomerate theory of competitive harm, and might pose new antitrust risks for transactions beyond the pharmaceutical sector, say attorneys at WilmerHale.

  • 5 Management Tips To Keep Law Firm Merger Talks Moving

    Author Photo

    Many law firm mergers that make solid business sense still fall apart due to the costs and frustrations of inefficient negotiations, but firm managers can increase the chance of success by effectively planning and executing merger discussions, say Lisa Smith and Kristin Stark at Fairfax Associates.

  • What 3rd Circ. Niaspan Decision Means For Class Cert.

    Author Photo

    The Third Circuit's recent denial of class certification in the Niaspan antitrust case underscores its particularly stringent understanding of the implicit ascertainability requirement, which further fuels confusion in the courts, threatens uneven results and increases the risk of forum shopping, says Michael Lazaroff at Rimon Law.

  • The Texas Two-Step May Be Losing Steam

    Author Photo

    The Texas Two-Step is a powerful bankruptcy strategy that has been used in recent high-profile cases, including Johnson & Johnson’s talc unit bankruptcy case, but ongoing debate and legal challenges raise the question of whether this maneuver is losing reliability, say Brendan Best and Justin Allen at Varnum.

  • FTC Pharma Merger Digest May Offer Policy Clues

    Author Photo

    The Federal Trade Commission's and the U.S. Justice Department's recently published summary of the agencies' workshop on proposed changes to pharmaceutical merger analysis reads like a policy roadmap and its timing may forecast the release of new draft merger guidelines, say attorneys at Mintz.